CA3222788A1 - Depletion de cellules stellaires hepatiques activees (csh) et leurs utilisations - Google Patents

Depletion de cellules stellaires hepatiques activees (csh) et leurs utilisations Download PDF

Info

Publication number
CA3222788A1
CA3222788A1 CA3222788A CA3222788A CA3222788A1 CA 3222788 A1 CA3222788 A1 CA 3222788A1 CA 3222788 A CA3222788 A CA 3222788A CA 3222788 A CA3222788 A CA 3222788A CA 3222788 A1 CA3222788 A1 CA 3222788A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
binding molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3222788A
Other languages
English (en)
Inventor
Chris Xiangyang Lu
Xiang-Ju Justin Gu
Minhua Zhang
Ruipeng ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laekna Therapeutics Shanghai Co Ltd
Original Assignee
Laekna Therapeutics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekna Therapeutics Shanghai Co Ltd filed Critical Laekna Therapeutics Shanghai Co Ltd
Publication of CA3222788A1 publication Critical patent/CA3222788A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une molécule de liaison qui comprend un domaine de liaison qui se lie à un antigène exprimé sur des cellules stellaires hépatiques activées (CSH), et un domaine fonctionnel qui est capable d'améliorer une fonction effectrice d'anticorps telle que la cytotoxicité à médiation cellulaire dépendante des anticorps (ADCC) vis-à-vis des CSH activées. L'invention concerne également des utilisations de ladite molécule de liaison.
CA3222788A 2021-07-02 2022-06-30 Depletion de cellules stellaires hepatiques activees (csh) et leurs utilisations Pending CA3222788A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021104201 2021-07-02
CNPCT/CN2021/104201 2021-07-02
PCT/CN2022/102692 WO2023274352A1 (fr) 2021-07-02 2022-06-30 Déplétion de cellules stellaires hépatiques activées (csh) et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3222788A1 true CA3222788A1 (fr) 2023-01-05

Family

ID=84691485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3222788A Pending CA3222788A1 (fr) 2021-07-02 2022-06-30 Depletion de cellules stellaires hepatiques activees (csh) et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4363443A1 (fr)
CN (1) CN117980328A (fr)
AU (1) AU2022304943A1 (fr)
CA (1) CA3222788A1 (fr)
IL (1) IL309804A (fr)
TW (1) TW202317632A (fr)
WO (1) WO2023274352A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492463B (zh) * 2023-03-31 2023-11-17 珠海市人民医院 Cd155分子在肝纤维化领域中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011265460B2 (en) * 2003-01-09 2014-07-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2012261721A1 (en) * 2006-03-17 2013-01-10 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
EP2673297A2 (fr) * 2011-02-11 2013-12-18 Zyngenia, Inc. Complexes plurispécifiques monovalents et multivalents et leurs utilisations
CN104628866B (zh) * 2015-01-21 2018-03-27 中国药科大学 一种靶向vegfr2的抗体融合蛋白的制备及其用途
CN104592395B (zh) * 2015-01-27 2017-11-14 中国药科大学 Vegfr2单链抗体与mica融合蛋白的制备方法及用途
CN108779175B (zh) * 2015-12-28 2022-07-08 依奈特制药公司 NKp46结合蛋白的可变区
PL3347379T3 (pl) * 2016-08-17 2020-05-18 Compugen Ltd. Przeciwciała anty-tigit, przeciwciała anty-pvrig i ich połączenia
KR20200135313A (ko) * 2018-02-26 2020-12-02 제넨테크, 인크. 항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CA3140055A1 (fr) * 2019-05-16 2020-11-19 Shattuck Labs, Inc. Proteines chimeriques dirigees par des cellules nk

Also Published As

Publication number Publication date
TW202317632A (zh) 2023-05-01
CN117980328A (zh) 2024-05-03
IL309804A (en) 2024-02-01
WO2023274352A1 (fr) 2023-01-05
AU2022304943A1 (en) 2024-01-18
EP4363443A1 (fr) 2024-05-08

Similar Documents

Publication Publication Date Title
US20230192841A1 (en) Claudin18.2 binding moieties and uses thereof
CA3163794A1 (fr) Anticorps a domaine unique et recepteurs antigeniques chimeriques ciblant bcma et leurs procedes d'utilisation
US20240059794A1 (en) Gucy2c binding molecules and uses thereof
WO2021170100A1 (fr) Anticorps et récepteurs antigéniques chimériques ciblant le glypicane-3 (gpc3) et leurs procédés d'utilisation
WO2023274352A1 (fr) Déplétion de cellules stellaires hépatiques activées (csh) et leurs utilisations
WO2022012680A1 (fr) Molécules de liaison à cd20 et leurs utilisations
KR20240070496A (ko) 활성화된 간 성상세포(hscs)의 고갈 및 이의 용도
WO2024041650A1 (fr) Récepteurs antigéniques chimériques ciblant la sous-unité alpha 2 du récepteur de l'interleukine 13 et leurs procédés d'utilisation
WO2024022512A1 (fr) Fractions de liaison à la claudine 6 et leurs utilisations
WO2024067762A1 (fr) Anticorps et récepteurs antigéniques chimériques ciblant gcc et leurs procédés d'utilisation
WO2023030503A1 (fr) Anticorps anti-acvr2a et leurs utilisations
WO2022012682A1 (fr) Molécules de liaison à cd22 et leurs utilisations
US20230192883A1 (en) Cd19 binding molecules and uses thereof
CA3211501A1 (fr) Materiaux et procedes de ciblage de lymphocytes t regulateurs pour l'amelioration de la surveillance immunitaire
TW202337904A (zh) ＩＬ－１β結合蛋白之材料及方法